Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ritonavir

FDA-approved product (solution, oral), marketed as Norvir, Ritonavir.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Ritonavir
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Chronic hepatitis C virus infection
  • Hepatitis C virus infection
  • HIV infection
  • HIV-1 infection
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Protease inhibitors
FDA pharmacologic class
Cytochrome P450 3A Inhibitor; Protease Inhibitor FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AE03

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA49.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli41.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae22.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis54.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Ritonavir in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ritonavir with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Atazanavir or Boosted Atazanavir Substitution for Ritonavir Boosted PI in Patients With Hyperlipidemia

    NCT00160329 · start 2004-01

    Registered record
    Registry ID
    NCT00160329
    Conditions
    Hyperlipidemia; HIV Infections
    Interventions
    Atazanavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2004-01
    Completion
    2009-03
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHyperlipidemia; HIV Infections
    InterventionAtazanavir
    PhasePhase 3
    Registry statusCompleted

  • Randomised Trial of Structured Treatment Interruption of HAART in HIV-Infected Adults in Abidjan (ANRS 1269 TRIVACAN)

    NCT00158405 · start 2002-12

    Registered record
    Registry ID
    NCT00158405
    Conditions
    HIV Infections
    Interventions
    Structured Treatment Interruption; Zidovudine (ZDV); Lamivudine (3TC); Efavirenz (EFV); Ritonavir (NRV); Indinavir (IDV)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2002-12
    Completion
    2006-12
    Enrolment
    840

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionStructured Treatment Interruption; Zidovudine (ZDV); Lamivudine (3TC); Efavirenz (EFV) +2 more
    PhasePhase 3
    Registry statusCompleted

  • Study of Adherence Effects and Clinical Outcomes of Kaletra Based HIV Antiviral Therapy

    NCT00234962 · start 2002-08

    Registered record
    Registry ID
    NCT00234962
    Conditions
    HIV Infection
    Interventions
    Lopinavir/Ritonavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2002-08
    Completion
    2007-02
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection
    InterventionLopinavir/Ritonavir
    PhasePhase 4
    Registry statusTerminated

  • A Study To Assess GW433908 (Fosamprenavir) Containing Regimens In HIV-1 Infected Subjects

    NCT00296504 · start 2001-11

    Registered record
    Registry ID
    NCT00296504
    Conditions
    Infection, Human Immunodeficiency Virus
    Interventions
    fosamprenavir (GW433908); ritonavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2001-11
    Completion
    2010-10
    Enrolment
    753

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection, Human Immunodeficiency Virus
    Interventionfosamprenavir (GW433908); ritonavir
    PhasePhase 3
    Registry statusCompleted

  • Long-term Effectiveness and Safety in Hepatitis-co-infected Patients

    NCT01153269 · start 2001-05

    Registered record
    Registry ID
    NCT01153269
    Conditions
    Human Immunodeficiency Virus-Infection
    Interventions
    Lopinavir/Ritonavir (Kaletra)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2001-05
    Completion
    2010-11
    Enrolment
    33

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHuman Immunodeficiency Virus-Infection
    InterventionLopinavir/Ritonavir (Kaletra)
    PhaseNot recorded
    Registry statusCompleted